Growing Market Presence HepQuant actively participates in major liver health conferences such as The Liver Meeting, DDW, and EASL, demonstrating its commitment to expanding the clinical adoption of its HepQuant DuO Test and enhancing market visibility among liver specialists and hepatology centers.

Innovative Non-Invasive Testing The company's focus on blood-based, quantitative liver testing positions it as a solution for healthcare providers seeking accurate, non-invasive alternatives to traditional liver assessments, creating opportunities to introduce its technology to clinics aiming to improve patient care and reduce reliance on invasive procedures.

Engaged with Thought Leaders HepQuant’s presentation of research at prominent medical events indicates strong engagement with thought leaders in hepatology and drug development, providing avenues to build strategic partnerships with key opinion leaders and research institutions for pilot studies or early adoption.

Relatively Small but Growing Revenue With annual revenue estimated between 1M to 10M and expanding clinical demonstration efforts, there is substantial growth potential for sales teams to target hepatology clinics, specialty labs, and healthcare systems interested in adopting advanced liver diagnostics.

Market Differentiation Opportunity HepQuant's ability to quantify liver function and physiological heterogeneity uniquely positions it to address unmet needs in liver disease management, providing sales opportunities to differentiate itself in a competitive diagnostics landscape through targeted outreach to specialists and research institutions.